Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.

ABSTRACT: Purpose: Antiendocrine therapy remains the most effective treatment for estrogen receptor-positive (ER⁺) breast cancer, but development of resistance is a major clinical complication. Effective targeting of mechanisms that control the loss of ER dependency in breast cancer remains elusive. We analyzed breast cancer-associated fibroblasts (CAF), the largest component of the tumor microenvironment, as a factor contributing to ER expression levels and antiendocrine resistance.Experimental Design: Tissues from patients with ER⁺ breast cancer were analyzed for the presence of CD146-positive (CD146^pos) and CD146-negative (CD146^neg) fibroblasts. ER-dependent proliferation and tamoxifen sensitivity were evaluated in ER⁺ tumor cel

SUBMITTER: Brechbuhl HM 

PROVIDER: S-EPMC5378660 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature